Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Irvine, CA, May 03, 2018 -- TRIMEDYNE, INC. (OTCPINK “TMED”) today reported its financial results for its quarter ending on March 31, 2018.
For the quarter ended March 31, 2018, Trimedyne had revenues of $1,352,000, an increase of 21% from revenues of $1,119,000 for the prior year quarter. We had a net income for the current quarter of $24,000 or $0.20 per share, as compared to a net loss of $31,000 or $(0.25) per share for the prior year quarter. The net income during the current quarter as compared to a net loss during the prior year quarter is a considerable improvement, which was primarily the result of an increase of export sales revenue and the continuation of our cost controls.
For the six-month period ended March 31, 2018, Trimedyne had revenues of $2,886,000, an increase of 30% from revenues of $2,213,000 for the prior year six-month period. We had net income for the current six-month period of $110,000 or $0.90 per share, as compared to a net loss of $256,000 or $(2.09) per share for the prior year six-month period. The net income during the current six-month period as compared to a net loss during the prior year six-month period is a considerable improvement, which was primarily the result of an increase of export sales revenue and the continuation of our cost controls.
Commenting on the financial results for the quarter, Marvin P. Loeb, Sc.D., Chairman of Trimedyne, said: “Since we are no longer required to file periodic reports with the SEC, our Financial Statements are un-audited. However, we believe our Financial Statements have been prepared and contain all adjustments of a recurring nature that are necessary for a fair presentation of our operations and financial condition for the periods and dates shown.”
“We appreciate the patience of our shareholders, and we are working hard to improve our financial condition.”
If you would like a copy of the financial statements, please send an email to [email protected], and we will be happy to send it to you.
CONTACT: Jeffrey Rudner (949) 951-3800, Ext. 285 [email protected]
